Millions of Americans will be impacted (and it's personal)

Our most senior analyst has recently come forward with the most important, most personal financial story of his career. On the surface, it's the story of a pharmaceutical firm that could make you 400% beginning October 31... [Stansberry Digest] Millions of Americans Will Be Impacted (and It's Personal) --------------------------------------------------------------- Our most senior analyst has recently come forward with the most important, most personal financial story of his career. On the surface, it's the story of [a pharmaceutical firm that could make you 400%]( beginning October 31... But the story goes much deeper than that. Here's the thing: The analyst behind this story has worked at Stansberry for a long time. He was the first analyst ever hired back in the year 2000... And I've never seen him as passionate about a financial opportunity as he is right now.w Because this opportunity goes way beyond finances. See, this pharmaceutical firm has developed [a legitimate medical breakthrough.]( It's the first FDA-approved treatment that's clinically proven to slow the progression of an insidious and painfully common disease. This analyst personally knows about the pain this disease inflicts. He watched his dad suffer with it for nearly a decade, until it finally took his life. It was heartbreaking. And his story isn't unique. More than six million Americans are living with this disease right now. Every year, 500,000 more are newly diagnosed. And until now, there hasn't been a treatment of any kind that could do much of anything about it. [That's why this breakthrough is so exciting.]( We believe it's the medical breakthrough of the decade. And for this analyst, it's the most important investment story of his career. Again, he's been following the clinical research on this disease ever since it claimed his father. And he's been tracking this firm's work on its breakthrough treatment for at least seven years. I hope you'll take a few minutes to [watch this message in full.]( It's short, and it includes a special invitation to try this analyst's research service, Stansberry Venture Technology, at the lowest entry price it's ever been offered in company history. In fact, it's a price so low, we can only offer it for 72 hours... and that time expires at midnight tonight. [Click here for the full details now.]( Regards, Matt Weinschenk Director of Research, Stansberry Research Published by Stansberry Research. You have received this e-mail as part of your subscription to Stansberry Digest . If you no longer wish to receive special offers from Stansberry Digest, [click here](. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2023 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 [stansberryresearch.com](.